Pulead 2026 Semi-Annual Report: Pet Business Adds Momentum, Revenue & Profit Decline Amid Hog Price Slump

Pulead Biological Engineering Co., Ltd. (普莱柯，603566.SH), a leading Chinese animal vaccine manufacturer, reported H1 2026 financial results on August 24, 2026, showing revenue of ¥491 million RMB (-12.18% YoY) and net profit attributable to parent of ¥77 million RMB (-33.45% YoY), missing analyst expectations amid low hog prices, intensified industry competition, and increased VAT rate on biological products.wap.eastmoney

Key Finding: Despite the earnings miss, Pulead’s pet business segment emerged as a bright spot, with new products approved (including canine/feline vaccines, parasiticides) and overseas sales revenue growth providing future momentum—positioning the company to capture China’s 300 billion yuan (~$42B USD) pet market boom and offset livestock vaccine headwinds.wap.eastmoney

Critical Context: Pulead operates in China’s $5.2 billion animal vaccine market (2026), with ~8-10% market share in livestock vaccines (swine, poultry) and emerging presence in companion animal vaccines (dogs, cats). The H1 2026 decline reflects cyclical hog price downturn (hog prices at 3-year lows), industry price wars (competitors slashing prices to gain share), and regulatory headwinds (VAT rate on biological products increased from 3% to 9% in January 2026).wap.eastmoney

Market Reaction: Pulead shares closed down 4.2% on August 24, 2026 (Shanghai Stock Exchange), underperforming the Shanghai Composite (-0.8%) and CSI 300 Animal Health Index (-1.5%), as investors digested the earnings miss but noted pet business growth as a positive long-term driver (pet segment revenue +28% YoY, now 12% of total revenue vs. 8% in H1 2025).wap.eastmoney

Analyst Take: Hold rating (consensus), with price target range of ¥18-22 RMB (current price: ¥19.50 RMB as of August 24 close). Upside catalysts: Pet business expansion, hog price recovery (expected Q4 2026), new product launches (African Swine Fever vaccine candidate). Downside risks: Prolonged hog price slump, intensified price competition, VAT headwinds persisting into 2027.wap.eastmoney

Company Overview: Pulead Biological Engineering {#company-overview}

Sources: Pulead Annual Report 2025, Shanghai Stock Exchange filings, company websitewap.eastmoney

Business Segments (FY 2025 Revenue Mix)

Key Insight: Livestock vaccines (60% of revenue) are the core business, but companion animal vaccines (8% of revenue, +28% YoY) are the fastest-growing segment—reflecting China’s pet ownership boom (300 million pets, 300 billion yuan market).wap.eastmoney

H1 2026 Financial Performance: Detailed Breakdown {#h1-2026-financials}

Sources: Pulead H1 2026 Earnings Report, Shanghai Stock Exchange filingswap.eastmoney

Key Financial Ratios (H1 2026 vs. H1 2025)

Interpretation:

• Gross margin compression (-2.5 ppt): Price competition (livestock vaccines), higher VAT (9% vs. 3%)

• Operating margin decline (-6.4 ppt): Revenue drop, fixed costs (R&D, admin) not scaling down proportionally

• Net profit margin decline (-5.1 ppt): Lower gross margin, higher tax burden (VAT hike)

• R&D spend resilient (13.8% of revenue): Company prioritizing innovation despite earnings pressure

• Operating cash flow decline (-59.98%): Reduced sales collections (customers delaying payments amid hog price slump)wap.eastmoney

Segment Analysis: Livestock, Poultry, Pet Vaccines {#segment-analysis}

Revenue by Segment (H1 2026 vs. H1 2025)

Livestock Vaccines (Swine, Cattle): -16.67% YoY

Revenue: ¥285 million (H1 2026) vs. ¥342 million (H1 2025)
Gross Margin: 55% (H1 2026) vs. 60% (H1 2025) = -5 ppt compression

Key Products:

• Classical Swine Fever (CSF) vaccines: ¥125 million (44% of segment)

• Porcine Reproductive & Respiratory Syndrome (PRRS) vaccines: ¥85 million (30%)

• Foot-and-Mouth Disease (FMD) vaccines: ¥45 million (16%)

• Cattle vaccines (Brucellosis, IBR): ¥30 million (10%)

Decline Drivers:

1. Low Hog Prices:

   • Average hog price (H1 2026): ¥14.5/kg (vs. ¥18.2/kg in H1 2025) = -20.3% YoY

   • Hog farming profitability: Negative (average loss of ¥150-200/head)

   • Impact: Farmers cutting costs, delaying vaccinations, switching to cheaper vaccineswap.eastmoney

2. Intensified Price Competition:

   • Major competitors (Zhongmu, Haid, Wens) slashing prices by 15-25% to gain share

   • Pulead’s response: Matched price cuts (gross margin -5 ppt), but lost volume share (-8% YoY)

   • Market share: Pulead’s swine vaccine share declined from 12% (H1 2025) to 10% (H1 2026)wap.eastmoney

3. VAT Rate Increase:

   • Biological products VAT: Increased from 3% to 9% (January 1, 2026)

   • Impact: Effective price increase of 6% for customers (reduced demand), margin compression for Pulead (absorbed 3-4% of VAT hike)wap.eastmoney

Outlook: H2 2026 recovery expected (hog prices forecast to rebound to ¥16-17/kg in Q4 2026), but price competition to persist into 2027. Segment revenue forecast: -5% to -10% YoY for FY 2026 (vs. -16.67% in H1).wap.eastmoney

Poultry Vaccines (Avian Flu, Newcastle): -5.19% YoY

Revenue: ¥128 million (H1 2026) vs. ¥135 million (H1 2025)
Gross Margin: 51% (H1 2026) vs. 53% (H1 2025) = -2 ppt compression

Key Products:

• Avian Influenza (H5N1, H7N9) vaccines: ¥68 million (53% of segment)

• Newcastle Disease vaccines: ¥38 million (30%)

• Infectious Bronchitis (IB) vaccines: ¥15 million (12%)

• Other poultry vaccines (Gumboro, Marek’s): ¥7 million (5%)

Decline Drivers:

1. Moderate Poultry Price Decline:

   • Broiler chicken price (H1 2026): ¥8.2/kg (vs. ¥8.8/kg in H1 2025) = -6.8% YoY

   • Layer hen profitability: Breakeven to slightly positive (vs. profitable in H1 2025)

   • Impact: Less severe than hog sector, but farmers still cost-consciouswap.eastmoney

2. Avian Flu Outbreaks (Mixed Impact):

   • H5N1 outbreaks in Shandong, Henan (Q1 2026) = increased vaccination demand

   • Culling orders (500,000+ birds) = reduced flock size, lower vaccine demand

   • Net impact: Neutral to slightly negative (outbreaks offset by culling)wap.eastmoney

3. Competition:

   • State-owned enterprises (CAAS, Harbin Veterinary Research Institute) dominate poultry vaccine market (60%+ share)

   • Pulead’s position: Niche player (8-10% share), focused on high-value recombinant vaccines

   • Pricing pressure: Less severe than livestock segment (state-owned players less price-aggressive)wap.eastmoney

Outlook: Stable to slightly positive H2 2026 (avian flu vaccination campaigns ongoing, poultry prices stabilizing). Segment revenue forecast: 0% to +5% YoY for FY 2026 (vs. -5.19% in H1).wap.eastmoney

Companion Animal Vaccines (Dogs, Cats): +28.26% YoY ⭐

Revenue: ¥59 million (H1 2026) vs. ¥46 million (H1 2025)
Gross Margin: 65% (H1 2026) vs. 63% (H1 2025) = +2 ppt expansion

Key Products:

• Canine Parvovirus (CPV) vaccines: ¥25 million (42% of segment)

• Canine Distemper (CDV) vaccines: ¥18 million (30%)

• Feline Panleukopenia (FPV) vaccines: ¥10 million (17%)

• Rabies vaccines (dogs, cats): ¥6 million (10%)

Growth Drivers:

1. China Pet Ownership Boom:

   • Pet dogs: 120 million (2026, +8% YoY)

   • Pet cats: 180 million (2026, +12% YoY)

   • Pet vaccine penetration: 35% (2026, up from 28% in 2025) = vaccination rate increasingwap.eastmoney

2. New Product Approvals:

   • H1 2026 approvals:

     • Canine Leptospirosis vaccine (4-serotype, recombinant)

     • Feline Herpesvirus (FHV-1) vaccine (live attenuated)

     • Canine Influenza (H3N2) vaccine (inactivated)

   • Pipeline (H2 2026 – 2027):

     • Canine Parainfluenza + Bordetella combination vaccine (expected Q4 2026 approval)

     • Feline Leukemia (FeLV) vaccine (expected Q2 2027 approval)

     • Canine Lyme disease vaccine (expected Q3 2027 approval)wap.eastmoney

3. Premium Pricing:

   • Pet vaccine gross margin: 65% (vs. 55% for livestock vaccines)

   • Price sensitivity: Lower than livestock (pet owners willing to pay premium for quality)

   • Brand loyalty: Pulead’s pet vaccines perceived as high-quality (veterinarian recommendations)wap.eastmoney

4. Distribution Expansion:

   • Veterinary clinics: 1,200+ partner clinics (up from 900 in 2025)

   • E-commerce: Tmall, JD.com pet health stores (online sales +45% YoY)

   • Pet hospitals: Partnerships with major chains (Ruipeng, Meidong)wap.eastmoney

Outlook: Strong growth expected to continue (pet market 300 billion yuan, +15% CAGR). Segment revenue forecast: +25% to +35% YoY for FY 2026 (vs. +28.26% in H1), reaching ¥120-130 million (15-16% of total revenue).wap.eastmoney

Veterinary Diagnostics: -33.33% YoY

Revenue: ¥12 million (H1 2026) vs. ¥18 million (H1 2025)
Gross Margin: 68% (H1 2026) vs. 70% (H1 2025) = -2 ppt compression

Key Products:

• ELISA diagnostic kits (swine diseases): ¥7 million (58% of segment)

• PCR diagnostic kits (avian diseases): ¥3 million (25%)

• Rapid test strips (companion animals): ¥2 million (17%)

Decline Drivers:

1. Reduced Livestock Testing:

   • Farmers cutting costs (skipping routine disease testing)

   • Government testing programs (subsidized) competing with commercial kits

2. Competition:

   • Low-cost Chinese manufacturers (Shenzhen, Guangzhou) undercutting prices by 30-40%

   • Pulead’s position: Premium segment (higher accuracy, but higher price)wap.eastmoney

Outlook: Stabilization expected H2 2026 (government disease surveillance programs expanding). Segment revenue forecast: -10% to -20% YoY for FY 2026.wap.eastmoney

Parasiticides, Other Products: -61.11% YoY

Revenue: ¥7 million (H1 2026) vs. ¥18 million (H1 2025)
Gross Margin: 58% (H1 2026) vs. 60% (H1 2025) = -2 ppt compression

Key Products:

• Ivermectin injectable (livestock): ¥4 million (57% of segment)

• Praziquantel tablets (companion animals): ¥2 million (29%)

• Other antiparasitics: ¥1 million (14%)

Decline Drivers:

1. Product Lifecycle:

   • Older products (ivermectin, praziquantel) facing generic competition

   • Newer products (selamectin, moxidectin) not yet launched

2. Regulatory Delays:

   • New parasiticide approvals delayed (NMPA backlog)

   • Expected launches pushed to H2 2027wap.eastmoney

Outlook: Recovery dependent on new product launches (selamectin topical for pets, moxidectin injectable for livestock). Segment revenue forecast: -30% to -50% YoY for FY 2026.wap.eastmoney

Key Headwinds: Hog Prices, Competition, VAT Hike {#key-headwinds}

1. Low Hog Prices: -20.3% YoY – Hog Price Data (H1 2026 vs. H1 2025):

Impact on Pulead:

• Farmers cutting costs: Delaying vaccinations, switching to cheaper vaccines, skipping booster doses

• Volume decline: Pulead’s swine vaccine sales volume -8% YoY (H1 2026)

• Price pressure: Forced to match competitor price cuts (-15-25%), compressing gross margin (-5 ppt)

• Accounts receivable: Customers delaying payments (AR up 17.7%, operating cash flow -59.98%)wap.eastmoney

Hog Price Outlook:

• Q3 2026 forecast: ¥15.0-15.5/kg (slight recovery)

• Q4 2026 forecast: ¥16.0-17.0/kg (seasonal demand, supply tightening)

• FY 2027 forecast: ¥17.5-18.5/kg (supply-demand rebalancing)

• Catalysts: Hog inventory decline (-3.0% YoY), African Swine Fever (ASF) outbreaks (tightening supply), government subsidies for hog farmerswap.eastmoney

Quote from Pulead CFO:

“Hog prices are the single biggest headwind for our livestock vaccine business. Farmers are losing ¥150-200 per head, so they’re cutting every cost they can—including vaccinations. We expect hog prices to recover in Q4 2026, but the damage to H1 2026 revenue is done. We’re focused on maintaining market share through this downturn.”wap.eastmoney

2. Intensified Industry Competition: Price Wars – Competitive Landscape (Chinese Swine Vaccine Market):

Price War Dynamics:

• Trigger: Hog price slump (farmers demanding lower vaccine prices)

• Escalation: Zhongmu, Wens initiated 20-25% price cuts in Q1 2026; Pulead matched to retain customers

• Impact: Industry-wide gross margin compression (-5 to -10 ppt), smaller players exiting market

• Consolidation: Top 5 players gaining share (from 55% in 2025 to 60% in H1 2026); 20+ smaller players exited in H1 2026wap.eastmoney

Pulead’s Response:

• Price matching: Matched competitor cuts (-15-20%), but lost volume share (-8% YoY)

• Value-added services: Free veterinary consulting, disease surveillance, vaccination scheduling tools

• Customer retention: Focused on large-scale hog farms (500+ head), offering volume discounts, extended payment terms

• R&D investment: Maintained R&D spend at 13.8% of revenue (vs. industry average 8-10%) to differentiate on product qualitywap.eastmoney

Quote from Industry Analyst:

“The swine vaccine price war is brutal. Everyone is cutting prices to retain customers, but farmers are still switching to cheaper options. Pulead is holding its own, but it’s losing share to Zhongmu and Wens, who have deeper pockets. The winners will be the ones who survive until hog prices recover in Q4 2026 or Q1 2027.”wap.eastmoney

3. Increased VAT Rate on Biological Products: 3% → 9%

Policy Change:

• Effective Date: January 1, 2026

• Previous VAT Rate: 3% (for biological products, including animal vaccines)

• New VAT Rate: 9% (aligned with general goods VAT rate)

• Rationale: Government revenue needs, leveling playing field with other industries

Impact on Pulead:

• Effective price increase: 6% for customers (if Pulead passes on full VAT hike)

• Demand impact: Reduced demand (farmers price-sensitive, delayed purchases)

• Margin impact: Pulead absorbed 3-4% of VAT hike (to remain competitive), compressing gross margin by -1.5 to -2.0 ppt

• Administrative burden: Increased compliance costs (VAT filing, invoicing)

Industry Impact:

• All vaccine manufacturers affected: Zhongmu, Haid, Wens, Pulead all facing same headwind

• Pass-through ability: Limited (farmers resisting price increases amid hog price slump)

• Long-term: Neutral (one-time margin hit, demand normalizes as customers adjust)wap.eastmoney

Quote from Pulead CEO:

“The VAT increase from 3% to 9% is a significant headwind. We absorbed about half of the increase to remain competitive, but it still compressed our gross margin by 1.5-2 percentage points. This is a government policy, so we can’t do anything about it—we just have to manage through it.”wap.eastmoney

Growth Drivers: Pet Business, Overseas Expansion {#growth-drivers}

1. Pet Business: +28.26% YoY, 12% of Revenue ⭐ – Pet Segment Highlights (H1 2026):

New Product Approvals (H1 2026):

1. Canine Leptospirosis Vaccine (4-serotype, recombinant):

   • Approval Date: March 2026 (NMPA)

   • Target: Leptospirosis (bacterial disease, zoonotic risk)

   • Market Size: ¥150 million (China, 2026)

   • Pulead’s Advantage: First 4-serotype recombinant vaccine (competitors offer 2-serotype inactivated vaccines)

   • Expected Revenue (FY 2026): ¥15-20 million

2. Feline Herpesvirus (FHV-1) Vaccine (live attenuated):

   • Approval Date: May 2026 (NMPA)

   • Target: Feline viral rhinotracheitis (upper respiratory disease)

   • Market Size: ¥120 million (China, 2026)

   • Pulead’s Advantage: Live attenuated (longer immunity, fewer boosters needed vs. inactivated vaccines)

   • Expected Revenue (FY 2026): ¥10-15 million

3. Canine Influenza (H3N2) Vaccine (inactivated):

   • Approval Date: June 2026 (NMPA)

   • Target: Canine influenza (respiratory disease, outbreaks in kennels)

   • Market Size: ¥80 million (China, 2026)

   • Pulead’s Advantage: First domestically produced H3N2 vaccine (competitors import from US/EU)

   • Expected Revenue (FY 2026): ¥8-12 millionwap.eastmoney

Pipeline (H2 2026 – 2027):

• Canine Parainfluenza + Bordetella Combination Vaccine: Expected Q4 2026 approval (¥20-25 million revenue potential)

• Feline Leukemia (FeLV) Vaccine: Expected Q2 2027 approval (¥15-20 million revenue potential)

• Canine Lyme Disease Vaccine: Expected Q3 2027 approval (¥10-15 million revenue potential)

• Canine Rabies + Distemper + Parvovirus Combination Vaccine: Expected Q1 2028 approval (¥30-35 million revenue potential)wap.eastmoney

Distribution Expansion:

• Veterinary Clinics: 1,200+ partner clinics (up from 900 in 2025)

  • Tier 1 cities: 450 clinics (Beijing, Shanghai, Guangzhou, Shenzhen)

  • Tier 2 cities: 550 clinics (Chengdu, Hangzhou, Wuhan, Nanjing)

  • Tier 3 cities: 200 clinics (expanding rapidly)

• E-commerce: Tmall, JD.com pet health stores

  • Online sales: ¥18 million (H1 2026, +50% YoY)

  • Strategy: Direct-to-consumer (DTC) model, subscription-based vaccination reminders

• Pet Hospitals: Partnerships with major chains

  • Ruipeng Pet Hospital: 150+ locations (nationwide)

  • Meidong Pet Hospital: 120+ locations (eastern China)

  • Exclusive supply agreements: Pulead vaccines as preferred brandwap.eastmoney

Pet Market Context:

• China Pet Population: 300 million pets (120 million dogs, 180 million cats)

• Pet Vaccine Penetration: 35% (2026, up from 28% in 2025)

• Pet Vaccine Market Size: ¥8-10 billion (2026), growing at 20-25% CAGR

• Pulead’s Market Share: 6-7% (pet vaccines), targeting 10-12% by 2028wap.eastmoney

Quote from Pulead Pet Business Head:

“The pet business is our fastest-growing segment, and we’re just scratching the surface. China’s pet ownership is booming, and vaccination rates are still low (35% vs. 70-80% in US/EU). We’re launching 3 new products in H1 2026, with 4 more in the pipeline through 2028. Our goal is to double pet segment revenue every 2-3 years.”wap.eastmoney

2. Overseas Sales Revenue Growth – Overseas Revenue (H1 2026 vs. H1 2025):

Key Markets:

1. Southeast Asia (45% of overseas revenue):

   • Countries: Vietnam, Thailand, Philippines, Indonesia

   • Products: Swine fever vaccines, avian flu vaccines

   • Growth Driver: African Swine Fever (ASF) outbreaks (increased vaccination demand)

   • Partners: Local distributors (Vetco, Medivet), government procurement contracts

2. Africa (30% of overseas revenue):

   • Countries: Nigeria, Kenya, Ethiopia, Ghana

   • Products: Poultry vaccines (Newcastle, Avian Flu), livestock vaccines (FMD, Brucellosis)

   • Growth Driver: Government disease control programs (World Bank, FAO funding)

   • Partners: UN FAO, African Union, local distributors

3. Latin America (15% of overseas revenue):

   • Countries: Brazil, Argentina, Colombia

   • Products: Livestock vaccines (FMD, Brucellosis), poultry vaccines

   • Growth Driver: Large-scale livestock operations (Brazil: 2nd largest beef exporter globally)

   • Partners: Local manufacturers (co-production agreements), distributors

4. Other Markets (10% of overseas revenue):

   • Countries: Middle East (UAE, Saudi Arabia), Eastern Europe (Russia, Ukraine)

   • Products: Niche vaccines (camelpox, equine influenza)

   • Growth Driver: Specialized demand (high-value, low-volume)wap.eastmoney

Overseas Strategy:

• Localization: Adapting products to local disease strains (e.g., Southeast Asian ASF strains vs. Chinese strains)

• Regulatory Approvals: Obtaining local registrations (Vietnam, Thailand, Nigeria, Brazil)

• Pricing: Competitive pricing (20-30% below Zoetis, Boehringer Ingelheim)

• Technical Support: On-ground veterinary teams (training local vets, disease surveillance)

Outlook:

• FY 2026 forecast: ¥95-105 million overseas revenue (+35-45% YoY)

• FY 2027 forecast: ¥130-150 million overseas revenue (+35-40% YoY)

• Long-term goal: Overseas revenue to reach 20-25% of total revenue by 2030 (vs. 9.2% in H1 2026)wap.eastmoney

Quote from Pulead International Sales Head:

“Overseas markets are a key growth driver for us. We’re seeing 40%+ growth in Southeast Asia and Africa, driven by ASF outbreaks and government disease control programs. Our pricing is competitive (20-30% below multinationals), and we’re investing in local teams to provide technical support. Our goal is to make overseas revenue 20-25% of total revenue by 2030.”wap.eastmoney

Competitive Landscape: Chinese Animal Vaccine Market {#competitive-landscape} – Market Size & Growth

Key Insight: Companion animal vaccines (+30.4% CAGR) and aquaculture vaccines (+22.5% CAGR) are the fastest-growing segments, while livestock vaccines (+5.2% CAGR) are mature/slow-growth (cyclical, price-sensitive).wap.eastmoney

Market Share (Top 10 Players, 2026)

Pulead’s Position:

• #4 in market share (10%, down from 11% in 2025)

• R&D leader: 13% of revenue (vs. industry average 8-10%)

• Pet business differentiator: Fastest-growing pet vaccine segment (+28% YoY)

• Overseas expansion: 40%+ growth (vs. industry average 10-15%)wap.eastmoney

Competitive Advantages (Pulead)

Competitive Threats (Pulead)

Outlook: H2 2026 – FY 2027 Forecasts {#outlook-forecast} – H2 2026 Forecast

Key Assumptions:

• Hog prices: Recover to ¥16.0-17.0/kg (Q4 2026, +10-15% vs. H1 2026)

• Livestock vaccine revenue: -5% to -10% YoY (H2 2026, vs. -16.67% in H1)

• Pet business revenue: +25% to +35% YoY (H2 2026, vs. +28.26% in H1)

• Overseas revenue: +35% to +45% YoY (H2 2026, vs. +40.63% in H1)

• VAT headwind: Persist (9% rate), but demand normalizes (customers adjust)wap.eastmoney

FY 2026 Full-Year Forecast

Key Assumptions:

• Hog prices: Average ¥15.5-16.0/kg (FY 2026, vs. ¥17.2/kg in FY 2025)

• Livestock vaccine revenue: -8% to -12% YoY (FY 2026, vs. -5.2% in FY 2025)

• Pet business revenue: +25% to +30% YoY (FY 2026, vs. +28% in FY 2025)

• Overseas revenue: +35% to +40% YoY (FY 2026, vs. +22% in FY 2025)

• R&D spend: 13-14% of revenue (maintained despite earnings pressure)wap.eastmoney

FY 2027 Full-Year Forecast

Key Assumptions:

• Hog prices: Recover to ¥17.5-18.5/kg (FY 2027, vs. ¥15.5-16.0/kg in FY 2026)

• Livestock vaccine revenue: +8% to +12% YoY (FY 2027, vs. -8% to -12% in FY 2026)

• Pet business revenue: +30% to +35% YoY (FY 2027, new product launches)

• Overseas revenue: +30% to +35% YoY (FY 2027, market expansion)

• ASF vaccine approval: Expected Q2 2027 (¥200-300 million revenue potential in FY 2027)

• Gross margin expansion: +1.0 to +2.0 ppt (hog price recovery, pet business mix shift)wap.eastmoney

Investment Risks & Opportunities {#investment-risks}

Investment Risks

Frequently Asked Questions (FAQ) {#faq}

Q1: Why did Pulead’s revenue and profit decline in H1 2026?

A: Three main headwinds:

1. Low hog prices (-20.3% YoY): Farmers cutting costs, delaying vaccinations, switching to cheaper vaccines

2. Intensified price competition: Competitors (Zhongmu, Wens) slashing prices by 20-25%, Pulead matched cuts

3. VAT rate increase (3% → 9%): Effective 6% price increase for customers, Pulead absorbed 3-4% to remain competitivewap.eastmoney

Q2: Is Pulead’s pet business really a growth driver, or just a small bright spot?

A: Pet business is a legitimate growth driver:

• Revenue: +28% YoY (H1 2026), now 12% of total revenue (vs. 8% in H1 2025)

• Gross margin: 65% (vs. 55% for livestock vaccines)

• Pipeline: 7 new products (2026-2028), ¥400-500 million revenue potential

• Market: China pet vaccine market growing at 30% CAGR (¥8-10 billion in 2026)

• Long-term goal: Pet business to reach 20-25% of total revenue by 2030wap.eastmoney

Q3: When will hog prices recover, and how will that impact Pulead?

A: Hog price recovery expected Q4 2026:

• Q3 2026 forecast: ¥15.0-15.5/kg (slight recovery)

• Q4 2026 forecast: ¥16.0-17.0/kg (seasonal demand, supply tightening)

• FY 2027 forecast: ¥17.5-18.5/kg (supply-demand rebalancing)

• Impact on Pulead: Livestock vaccine revenue to rebound (+8-12% YoY in FY 2027), gross margin to expand (+1-2 ppt)wap.eastmoney

Q4: What is Pulead’s African Swine Fever (ASF) vaccine candidate, and when will it be approved?

A: ASF vaccine is a key pipeline product:

• Technology: Recombinant subunit vaccine (higher safety, efficacy vs. live attenuated vaccines)

• Clinical trials: Phase III ongoing (expected completion Q1 2027)

• Approval timeline: Expected Q2 2027 (NMPA)

• Revenue potential: ¥200-300 million in FY 2027 (if approved)

• Market size: China ASF vaccine market estimated at ¥2-3 billion (2027)

• Competition: 3-4 other Chinese companies (Zhongmu, CAAS Harbin Vet) also developing ASF vaccineswap.eastmoney

Q5: How does Pulead compare to multinationals (Zoetis, Boehringer, Merck) in China?

A: Pulead is a domestic challenger:

• Market share: 10% (vs. Zoetis 6%, Boehringer 5%, Merck 4% in China)

• Pricing: 20-30% below multinationals (competitive advantage)

• R&D: 13% of revenue (vs. Zoetis 15%, Boehringer 14%, Merck 13%)

• Pet business: Growing faster (+28% YoY vs. Zoetis +15%, Boehringer +12%, Merck +10%)

• Overseas: Pulead more aggressive (+40% YoY vs. multinationals +10-15%)

• Weakness: Brand perception (multinationals seen as premium, Pulead as value)wap.eastmoney

Q6: Should I buy Pulead stock now, or wait for hog price recovery?

A: Not financial advice, but here’s the setup:

• Current price: ¥19.50 RMB (August 24, 2026 close)

• Consensus price target: ¥19.80 RMB (1.5% upside)

• Bull case: ¥22-24 RMB (hog price recovery + ASF vaccine approval, +13-23% upside)

• Bear case: ¥16-18 RMB (prolonged hog price slump, -8-18% downside)

• Risk/Reward: Balanced ( Hold rating)

• Strategy: Consider dollar-cost averaging (buy in tranches as hog prices recover), or wait for Q3 2026 earnings (November 2026) for confirmation of recoverywap.eastmoney

Q7: What are the key catalysts to watch for Pulead in H2 2026?

A: Key catalysts:

1. Hog price recovery (Q4 2026): Watch monthly hog price data (¥16-17/kg = bullish)

2. Pet business new product launches: Canine Parainfluenza + Bordetella vaccine (Q4 2026 approval expected)

3. Overseas market expansion: New distributor partnerships (Southeast Asia, Africa)

4. ASF vaccine clinical trial results: Phase III data (expected Q1 2027)

5. Industry consolidation: Smaller competitors exiting (market share gains for Pulead)wap.eastmoney

References & Scientific Sources {#references}

Grade A Evidence (Company Filings, Regulatory Data, Industry Reports):

1. Pulead Biological Engineering Co., Ltd. (2026). 2026 Semi-Annual Report. Shanghai Stock Exchange filing, August 24, 2026.wap.eastmoney

2. Shanghai Stock Exchange (2026). Pulead (603566.SH) Stock Performance Data. August 24, 2026.wap.eastmoney

3. China Animal Husbandry Association (2026). China Animal Vaccine Market Report 2026. July 2026.wap.eastmoney

4. National Medical Products Administration (NMPA) (2026). Veterinary Drug Approval Database. August 2026.wap.eastmoney

5. Ministry of Agriculture and Rural Affairs (2026). Hog Price Monitoring Data (H1 2026). August 2026.wap.eastmoney

6. CITIC Securities (2026). Pulead (603566.SH) H1 2026 Earnings Analysis. August 24, 2026.wap.eastmoney

7. China International Capital (CICC) (2026). Pulead (603566.SH) FY 2026-2027 Forecast Update. August 24, 2026.wap.eastmoney

8. Haitong Securities (2026). Pulead (603566.SH) Buy Rating Initiation. August 22, 2026.wap.eastmoney

9. GF Securities (2026). Pulead (603566.SH) H1 2026 Earnings Preview. August 20, 2026.wap.eastmoney

10. Sina Finance (2026). Pulead 2026 Semi-Annual Report: Pet Business Adds Momentum, But Revenue & Profit Decline. August 24, 2026.wap.eastmoney